Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COB/FTC/TAF) is a coformulated
STR, is the only protease inhibitor based STR, and is noted for its high tolerability3. These
traits have the potential to improve adherence in patients who have intolerance to the
integrase inhibitor class. We propose a two part study design to evaluate if patients who
have suboptimal adherence due to integrase inhibitor intolerance may better tolerate Symtuza
and subsequently have improved adherence.